The main goal of this clinical trial is to determine if an investigational medication called VEL101 is safe, well tolerated, and effective in people receiving a new kidneytransplant. Participants will be randomly assigned to 2 different doses of VEL-101 or to tacrolimus, which is standardly used…
Kidneytransplant extends life, improves quality of life, and reduces healthcare costs. Unfortunately, there are not enough donated kidneys, so many people who need a transplant spend years on the waiting list. …
This is a 60-month adaptive to evaluate three siplizumab-based treatment regimens in kidneytransplant recipients. The purpose of this research study is to see if the anti-rejection medications that patients normally take after transplant can be reduced or stopped…
This purpose of this study is to understand the interaction between two different medications, tacrolimus and Paxlovid (nirmatrelvir/ritonavir), in patients who have had a kidneytransplant and are being treated by their doctor for COVID-19 infection. Tacrolimus is an oral medication that is used…
The purpose of this study is to determine if an investigational drug called tegoprubart (also known as AT1501) is safe and effective in preventing rejection in patients who are undergoing a kidneytransplant for the first time. Participants will be randomly assigned to tegoprubart or standard…
Subjects who undergo a kidneytransplant require long term use of anti-rejection (immunosuppressive)drugs to prevent their body's immune system from attacking and damaging the newly transplanted kidney (rejection).The purpose of this…
The purpose of this research study is to see if an investigational drug, BB3, is safe and effective forincreasing the amount of urine that a transplanted kidney will produce. An investigational drugis one that is not approved by the United States Food and Drug Administration (FDA). BB3 is agrowth…
Kidneytransplant patients are at a higher risk for bone fractures compared to the general population. We are doing a clinical trial to examine the effects of 12-months of treatment with denosumab, a monoclonal antibody against RANKL, on bone density and strength as determined by bone imaging and…
The MK-8228-002 Study is studying the safety and effectiveness of an investigational medication for preventing cytomegalovirus (CMV) disease in adults with kidneytransplants. The MK-8228-002 Study is evaluating an investigational medication (known as MK-8228) versus valganciclovir (VGCV). VGCV…
This research is being done to learn whether organ transplantation from HIV-positive deceased donors is as safe and effective in HIV-positive recipients as transplants from HIV-negative deceased donors. People with end-stage organ disease and HIV infection, and who qualify for organ…